⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 15, 2025Open Access

Table 3 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

Camila Bragança Xavier Clark R. Andersen JoAnn Lim Julian H. Slade Stacie A. Bean Lei Kang Hung Le Apostolia M. Tsimberidou Aung Naing David S. Hong Ecaterina E. Dumbrava Jordi Rodón Paula R. Pohlmann Sarina A. Piha‐Paul Stéphane Champiat Timothy A. Yap Tin‐Yun Tang Funda Meric‐Bernstam Siqing Fu

View Full Paper

Ask AI

Bookmark

Share

Key Points

Survival outcomes are affected by drug interactions in patients with solid tumors undergoing immunotherapy.
The analysis highlights variables influencing treatment efficacy, emphasizing the need for tailored approaches.
Assessment was performed using a phase I unit focusing on interactions between various therapeutic agents.
Understanding these interactions may enhance patient management and improve treatment strategies in solid tumors.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase I analysis reveals survival-variable interactions in solid tumors, indicating treatment optimization opportunities.

Abstract

Summary of variables related to survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xavier et al. (2025) studied this question.

synapsesocial.com/papers/68d4508931b076d99fa586b5 https://doi.org/10.1158/2767-9764.30126777

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
2Figure 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
3Data from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
4Figure 3 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
5Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 Unit2025 · 1 citations